Table 1.
Post-vaccine autoimmune hepatitis cases reported in the literature.
| Study | Sex and age | Vaccine | Latency (days) | GOT/GPT at diagnosis (U/L) | Bilirubin at diagnosis (mg/dl) | Antibodies | IgG | Biopsy compatible with HAI |
|---|---|---|---|---|---|---|---|---|
| Bril et al [5] | Female, 35 | Pfizer (1st dose) | 13 | 754/2001 | 4,8 | ANA Ds-DNA |
N | Yes |
| Londoño et al [6] | Female, 41 | Moderna (2nd dose) | 7 | 993/1312 | 2,3 | ANA, ASMA, SLA, LC1 | ↑ | Yes |
| Clayton-Chubb et al [7] | Male, 36 | AstraZeneca (1st dose) | 26 | 633/1774 | 1 | ANA | N | Yes |
| Tan et al [8] | Female, 56 | Moderna (1st dose) | 35 | 1124/1701 | 6 | ANA, ASMA | ↑ | Yes |
| McShane et al [9] | Female, 71 | Moderna (unknown) | 4 | ?/1067 | 12,1 | ASMA | ↑ | Yes |
| Lodato et al [10] | Female, 43 | Pfizer (1st dose) | 15 | 51/52 | 17,5 | – | N | Yes |
| Vuille-Lessard et al [11] | Female, 76 | Moderna (1st dose) | 3 | 811/579 | 6,5 | ANA, ASMA, AAA, p-ANCA | ↑ | Yes |
| Rela et al [12] | Female, 38 | AstraZeneca | 14 | 1101/1025 | 2,86 | ANA | ↑ | Yes |
| Male, 62 | AstraZeneca | 16 | 1361/1094 | 19,2 | – | – | Yes | |
| Tun et al [13] | Male, 47 | Moderna (1st dose) | 3 | --/1048 | 19 | negative | ↑ | Yes |
| Palla et al [14] | Female, 40 | Pfizer (2nd dose) | 30 | x4 ULN | – | ANA | ↑ | Yes |
| Rocco et al [15] | Female, 80 | Pfizer (2nd dose) | 7 | 1401/1186 | 10,5 | ANA | ↑ | Yes |
| Ghielmetti M et al [16] | Male, 63 | Moderna (1st dose) | 7 | 1127/1038 | 20,8 | ANA, atypical AMA | ↑ | Yes |
| Avci et al [17] | Female, 61 | Pfizer (1st dose) | 30 | 455/913 | 11,8 | ANA, ASMA | ↑ | Yes |
| Garrido et al [18] | Female, 65 | Moderna (1st dose) | 14 | 1056/1092 | 1,14 | ANA | ↑ | Yes |
| Goulas A et al [19] | Female, 52 | Moderna (1st dose) | 14 | 350/936 | 9,06 | ANA, ASMA | ↑ | Yes |
| Camacho-Domínguez et al [20] | Male, 79 | AstraZeneca (1st dose) | 27 | 2003/1994 | 11,9 | ANA, ASMA | ↑ | Yes |
| Erard et al [21] | Female, 80 | Pfizer (2nd dose) | 10 | 583/541 | 4,6 | ANA | ↑ | Yes |
| Female, 73 | Moderna (1st dose) | 21 | 1163/1027 | 19,5 | ANA | ↑ | Yes | |
| Female, 68 | AstraZeneca (1st dose) | 20 | 2314/2029 | 44 | ANA | ↑ | Yes | |
| Fimiano et al. [22] | Female, 63 | Pfizer (2nd dose) | 54 | 1625/1778 | 18,6 | Ac antitiroglobulina | ↑ | Yes |
| Ghorbani et al. [23] | Male, 62 | Sinopharm (2nd dose) | 3 | 435/722 | 8 | – | – | Yes |